Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles.
ComplicationsHyperlipoprotéinémieGestion
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs incluent l'obésité, le tabagisme, et une alimentation riche en graisses saturées.
Facteurs de risqueObésitéAlimentation
#2
L'âge influence-t-il le risque ?
Oui, le risque augmente avec l'âge, surtout après 45 ans chez les hommes et 55 ans chez les femmes.
ÂgeFacteurs de risqueHyperlipoprotéinémie
#3
Le stress a-t-il un impact sur cette condition ?
Oui, le stress chronique peut contribuer à des comportements malsains et à l'hyperlipoprotéinémie.
StressHyperlipoprotéinémieComportements malsains
#4
Les antécédents familiaux jouent-ils un rôle ?
Oui, des antécédents familiaux d'hyperlipoprotéinémie augmentent le risque.
Antécédents familiauxHyperlipoprotéinémieFacteurs de risque
#5
Le diabète est-il un facteur de risque ?
Oui, le diabète de type 2 est un facteur de risque majeur pour l'hyperlipoprotéinémie.
DiabèteHyperlipoprotéinémieFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hyperlipoprotéinémie de type II : Questions médicales les plus fréquentes",
"headline": "Hyperlipoprotéinémie de type II : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hyperlipoprotéinémie de type II : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-28",
"dateModified": "2025-03-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hyperlipoprotéinémie de type II"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Erreurs innées du métabolisme lipidique",
"url": "https://questionsmedicales.fr/mesh/D008052",
"about": {
"@type": "MedicalCondition",
"name": "Erreurs innées du métabolisme lipidique",
"code": {
"@type": "MedicalCode",
"code": "D008052",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C18.452.648.398"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hypercholestérolémie familiale homozygote",
"alternateName": "Homozygous Familial Hypercholesterolemia",
"url": "https://questionsmedicales.fr/mesh/D000090542",
"about": {
"@type": "MedicalCondition",
"name": "Hypercholestérolémie familiale homozygote",
"code": {
"@type": "MedicalCode",
"code": "D000090542",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C18.452.648.398.481.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hyperlipoprotéinémie de type II",
"alternateName": "Hyperlipoproteinemia Type II",
"code": {
"@type": "MedicalCode",
"code": "D006938",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Olga I Afanasieva",
"url": "https://questionsmedicales.fr/author/Olga%20I%20Afanasieva",
"affiliation": {
"@type": "Organization",
"name": "Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia."
}
},
{
"@type": "Person",
"name": "Marat V Ezhov",
"url": "https://questionsmedicales.fr/author/Marat%20V%20Ezhov",
"affiliation": {
"@type": "Organization",
"name": "A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia."
}
},
{
"@type": "Person",
"name": "Vincent A Pallazola",
"url": "https://questionsmedicales.fr/author/Vincent%20A%20Pallazola",
"affiliation": {
"@type": "Organization",
"name": "Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Vasanth Sathiyakumar",
"url": "https://questionsmedicales.fr/author/Vasanth%20Sathiyakumar",
"affiliation": {
"@type": "Organization",
"name": "Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA."
}
},
{
"@type": "Person",
"name": "Jihwan Park",
"url": "https://questionsmedicales.fr/author/Jihwan%20Park",
"affiliation": {
"@type": "Organization",
"name": "Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis.",
"datePublished": "2022-05-31",
"url": "https://questionsmedicales.fr/article/35639340",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40259-022-00537-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "The role of interleukin -1 family in fibrotic diseases.",
"datePublished": "2023-03-13",
"url": "https://questionsmedicales.fr/article/36921509",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cyto.2023.156161"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Role of the Interleukin-1 Family in Complications of Prematurity.",
"datePublished": "2023-02-01",
"url": "https://questionsmedicales.fr/article/36769133",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24032795"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Role of interleukin-1 in human diseases: pharmacotherapy prospects: A review].",
"datePublished": "2022-10-12",
"url": "https://questionsmedicales.fr/article/36286981",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.26442/00403660.2022.08.201781"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Role of Polymorphisms at the Interleukin-1, Interleukin-4, GATA-3 and Cyclooxygenase-2 Genes in Non-Surgical Periodontal Therapy.",
"datePublished": "2022-06-30",
"url": "https://questionsmedicales.fr/article/35806269",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23137266"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies métaboliques et nutritionnelles",
"item": "https://questionsmedicales.fr/mesh/D009750"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies métaboliques",
"item": "https://questionsmedicales.fr/mesh/D008659"
},
{
"@type": "ListItem",
"position": 4,
"name": "Erreurs innées du métabolisme",
"item": "https://questionsmedicales.fr/mesh/D008661"
},
{
"@type": "ListItem",
"position": 5,
"name": "Erreurs innées du métabolisme lipidique",
"item": "https://questionsmedicales.fr/mesh/D008052"
},
{
"@type": "ListItem",
"position": 6,
"name": "Hyperlipoprotéinémie de type II",
"item": "https://questionsmedicales.fr/mesh/D006938"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hyperlipoprotéinémie de type II - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hyperlipoprotéinémie de type II",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hyperlipoprotéinémie de type II",
"description": "Comment diagnostiquer l'hyperlipoprotéinémie de type II ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels niveaux de LDL indiquent ce type d'hyperlipoprotéinémie ?\nL'hyperlipoprotéinémie de type II est-elle héréditaire ?\nQuels symptômes peuvent indiquer un diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Interleukin-1#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hyperlipoprotéinémie de type II",
"description": "Quels sont les symptômes courants de cette condition ?\nPeut-on observer des dépôts cutanés ?\nL'hyperlipoprotéinémie de type II cause-t-elle des douleurs ?\nQuels signes cliniques peuvent apparaître ?\nY a-t-il des symptômes liés aux maladies cardiovasculaires ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Interleukin-1#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hyperlipoprotéinémie de type II",
"description": "Comment prévenir l'hyperlipoprotéinémie de type II ?\nLe contrôle du poids est-il important ?\nLe tabagisme influence-t-il cette condition ?\nLes examens réguliers sont-ils nécessaires ?\nL'éducation sur la santé est-elle utile ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Interleukin-1#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hyperlipoprotéinémie de type II",
"description": "Quels traitements sont disponibles pour cette condition ?\nLes changements de mode de vie sont-ils recommandés ?\nDes médicaments autres que les statines sont-ils utilisés ?\nQuelle est l'importance du suivi médical ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Interleukin-1#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hyperlipoprotéinémie de type II",
"description": "Quelles complications peuvent survenir ?\nL'hyperlipoprotéinémie de type II peut-elle causer des AVC ?\nY a-t-il un risque de crise cardiaque ?\nComment l'hyperlipoprotéinémie affecte-t-elle les reins ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Interleukin-1#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hyperlipoprotéinémie de type II",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLe stress a-t-il un impact sur cette condition ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe diabète est-il un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D006938?mesh_terms=Interleukin-1#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hyperlipoprotéinémie de type II ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic est établi par des analyses sanguines mesurant les niveaux de lipides."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le profil lipidique et éventuellement des tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels niveaux de LDL indiquent ce type d'hyperlipoprotéinémie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux de LDL supérieurs à 160 mg/dL sont souvent indicatifs."
}
},
{
"@type": "Question",
"name": "L'hyperlipoprotéinémie de type II est-elle héréditaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être héréditaire, souvent liée à des mutations génétiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, mais des dépôts de cholestérol peuvent apparaître sur la peau."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de cette condition ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des patients sont asymptomatiques, mais des douleurs thoraciques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Peut-on observer des dépôts cutanés ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des xanthomes peuvent se former sur la peau en raison de l'accumulation de lipides."
}
},
{
"@type": "Question",
"name": "L'hyperlipoprotéinémie de type II cause-t-elle des douleurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est généralement asymptomatique, mais peut entraîner des douleurs si des complications surviennent."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent apparaître ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des arcus cornéens peuvent être visibles chez certains patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes liés aux maladies cardiovasculaires ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme l'angine de poitrine peuvent survenir en cas de complications."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hyperlipoprotéinémie de type II ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier sont des mesures préventives clés."
}
},
{
"@type": "Question",
"name": "Le contrôle du poids est-il important ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, maintenir un poids santé aide à réduire le risque d'hyperlipoprotéinémie."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il cette condition ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de maladies cardiovasculaires associées."
}
},
{
"@type": "Question",
"name": "Les examens réguliers sont-ils nécessaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans lipidique réguliers aident à détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "L'éducation sur la santé est-elle utile ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sensibiliser à l'importance d'un mode de vie sain est essentiel pour la prévention."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour cette condition ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines sont couramment prescrites pour réduire les niveaux de LDL."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie sont-ils recommandés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation saine et l'exercice régulier sont essentiels pour la gestion."
}
},
{
"@type": "Question",
"name": "Des médicaments autres que les statines sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments comme les inhibiteurs de PCSK9 peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du suivi médical ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier est crucial pour ajuster le traitement et surveiller les niveaux de lipides."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec un suivi approprié, les traitements peuvent réduire significativement les risques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'athérosclérose et les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'hyperlipoprotéinémie de type II peut-elle causer des AVC ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle augmente le risque d'accidents vasculaires cérébraux en raison de l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de crise cardiaque ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés de LDL augmentent le risque de crise cardiaque."
}
},
{
"@type": "Question",
"name": "Comment l'hyperlipoprotéinémie affecte-t-elle les reins ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des maladies rénales en raison de l'athérosclérose des vaisseaux rénaux."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le tabagisme, et une alimentation riche en graisses saturées."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout après 45 ans chez les hommes et 55 ans chez les femmes."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur cette condition ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des comportements malsains et à l'hyperlipoprotéinémie."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'hyperlipoprotéinémie augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le diabète est-il un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète de type 2 est un facteur de risque majeur pour l'hyperlipoprotéinémie."
}
}
]
}
]
}
Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Hyperlipoprotéinémie de type II" :
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Hyperlipoprotéinémie de type II" :
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Hyperlipoprotéinémie de type II" :
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Welch Center for Prevention, Epidemiology, and Clinical Research, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Publications dans "Hyperlipoprotéinémie de type II" :
Provincial Key Laboratory of Biotechnology, Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an 710069, China.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.
Publications dans "Hyperlipoprotéinémie de type II" :
Although most patients with acute pericarditis will recover, a minority will have recurrent, debilitating episodes. In these patients, refractory symptoms result in high morbidity, and typically requi...
Fibrosis refers to the phenomenon that fibrous connective tissues are increased and parenchymal cells are decreased in organs or tissues such as lung, heart, liver, kidney, skin and so on. It usually ...
Preterm birth is a major contributor to neonatal morbidity and mortality. Complications of prematurity such as bronchopulmonary dysplasia (BPD, affecting the lung), pulmonary hypertension associated w...
According to current concepts, human immunoinflammatory diseases (IIDs), depending on the prevailing mechanisms of immunopathogenesis, are divided into two main categories: autoimmune and autoinflamma...
Periodontitis is a multifactorial disease. The aim of this explorative study was to investigate the role of Interleukin-(IL)-1, IL-4, GATA-3 and Cyclooxygenase-(COX)-2 polymorphisms after non-surgical...
The pro-inflammatory cytokine interleukin-1 (IL-1) drives the pathogenesis of several inflammatory diseases. Recent studies have revealed that 2-indolinones can modulate cytokine responses. Therefore,...
Epidemiological evidence for the link of interleukin 1 (IL-1) and its inhibition with cardiovascular diseases (CVDs) remains controversial. We aim to investigate the cardiovascular effects of IL-1 rec...
Genetic variants identified from a genome-wide association study involving 30,931 individuals were used as instrumental variables for the serum IL-1Ra concentrations. Genetic associations with CVDs an...
Genetically determined IL-1Ra level was associated with increased risk of coronary heart disease (CHD; OR, 1.07; 95% CI: 1.03-1.17) and myocardial infarction (OR, 1.13; 95% CI: 1.04-1.21). The main re...
Apolipoprotein B represents the key driver, and a potential target for reversal of the causal link between serum IL-1Ra and increased risk of CHD/MI. The combined therapy involving IL-1 inhibition and...
Interleukin (IL) 1, and its family member, IL-1 receptor antagonist (IL-1ra), are involved in the pathogenesis and inflammation perpetuation of patients with rheumatoid arthritis (RA). Besides, IL-1 h...
Bone morphogenic protein (BMP) signaling is critical for intestinal development, homeostasis, and function performance. Although the function of BMP signaling in the intestinal epithelium is well appr...
Interleukin-1 (IL-1) inhibitors are approved for treating familial Mediterranean fever (FMF) that is resistant to colchicine. However, continued concomitant treatment with colchicine is imperative, as...
The databases of Maccabi Health Services, a 2.6-million-member state-mandated health provider in Israel were searched for patients with FMF diagnosis. The medication possession ratio (MPR), calculated...
The final cohort included 4526 patients. Of them, 108 (2.4%) were with crFMF, and were matched to 432 with csFMF. The total mean MPR in each of the matched groups was similar (78.9 ± 41.4 and 82.5 ± 8...
In contrast to initial concerns, adherence to colchicine was similar between patients with crFMF and csFMF. However, in both groups, adherence to colchicine was poor. Education of both caregivers and ...